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1. INTRODUCTION {#dom13147-sec-0001}
===============

Sulphonylureas (SUs) are conventionally chosen as the treatment for type 2 diabetes mellitus (T2DM) after metformin failure[1](#dom13147-bib-0001){ref-type="ref"}; however, the glucose‐lowering effect of SUs tends to diminish as a function of time. Dipeptidyl peptidase‐4 (DPP‐4) inhibitors, a novel class of OADs that function to inhibit the DPP‐4 enzyme‐induced degradation of glucagon‐like peptide‐1, have become a widely accepted option for T2DM treatment in the past decade.[2](#dom13147-bib-0002){ref-type="ref"} Regarding the long‐term efficacy of DPP‐4 inhibitors for glycaemic control, although a recent meta‐analysis combining the results of long‐term clinical trials suggested that the effect of DPP‐4 inhibitors on glycated haemoglobin (HbA1c) levels in patients with T2DM may decline during the second year of treatment,[3](#dom13147-bib-0003){ref-type="ref"} conclusive results have not been obtained. More importantly, the results of pilot studies evaluating the comparative glycaemic durability of DPP‐4 inhibitors and SUs were not consistent[4](#dom13147-bib-0004){ref-type="ref"}, [5](#dom13147-bib-0005){ref-type="ref"}, [6](#dom13147-bib-0006){ref-type="ref"}, [7](#dom13147-bib-0007){ref-type="ref"}, [8](#dom13147-bib-0008){ref-type="ref"}, [9](#dom13147-bib-0009){ref-type="ref"}, [10](#dom13147-bib-0010){ref-type="ref"}, [11](#dom13147-bib-0011){ref-type="ref"}; therefore, the aim of the present study was to perform a meta‐analysis of long‐term randomized controlled trials (RCTs) to compare the glycaemic durability of DPP‐4 inhibitors and SUs in patients with T2DM, as reflected by the change in HbA1c levels from an intermediate time point (26 or 52 weeks) to 104 weeks of treatment.

2. METHODS {#dom13147-sec-0002}
==========

This meta‐analysis was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses)[12](#dom13147-bib-0012){ref-type="ref"} and the Cochrane Handbook guidelines.[13](#dom13147-bib-0013){ref-type="ref"}

2.1. Search strategy {#dom13147-sec-0003}
--------------------

The Medline (PubMed), Embase (Ovid), and CENTER (Cochrane Library) databases were systematically searched using the terms "DPP4," "DPP‐4," "dipeptidyl peptidase‐4 inhibitors," "sitagliptin," "vildagliptin," "linagliptin," "saxagliptin," "alogliptin," "dutogliptin," "aemigliptin," "anagliptin," "teneligliptin," "trelagliptin," or "omarigliptin" coupled with "glimepiride," "glipizide," "gliclazide," "glibenclamide," "glyburide," "gliguidone," "sulphonylureas," "sulfonylureas," and "random," "randomly," or "randomized." The final search was performed on January 25, 2017. The search was limited to clinical trials in humans. We also manually analysed the references of original and review articles to identify additional studies.

2.2. Criteria for study selection {#dom13147-sec-0004}
---------------------------------

Studies were included if they: (1) were full‐length articles in English or Chinese; (2) were RCTs with a parallel design; (3) recruited people with confirmed T2DM; (4) assigned patients to either an oral DPP‐4 inhibitor treatment group or an oral SU group; (5) had a treatment duration of at least 2 years (104 weeks); and (6) provided information necessary for extraction or estimation of data for changes in HbA1c levels from an intermediate time point (26 or 52 weeks) to 104 weeks.

2.3. Data extraction and quality assessment {#dom13147-sec-0005}
-------------------------------------------

Two authors independently performed the literature search, data extraction and quality assessment. Discrepancies were resolved by discussion with the corresponding author. The Cochrane Risk of Bias Tool with seven domains[13](#dom13147-bib-0013){ref-type="ref"} was applied for study quality evaluation.

2.4. Statistical analysis {#dom13147-sec-0006}
-------------------------

REVMAN (Version 5.1; Cochrane Collaboration, Oxford, UK) and STATA software (version 12.0; Stata Corporation, College Station, Texas) were used for statistical analysis. The primary outcome of this meta‐analysis was the change in HbA1c level from an intermediate time point (26 or 52 weeks) to 104 weeks of treatment with DPP‐4 inhibitors and SUs. If data for HbA1c levels at a certain intermediate time point were not reported, data for the nearest time‐point were used. The combined effect was presented as a mean difference (MD) with the 95% confidence interval (CI). Heterogeneity was evaluated with Cochrane\'s Q test,[13](#dom13147-bib-0013){ref-type="ref"} and significant heterogeneity was considered if *P* \< .10. The I^2^ statistic was determined to describe the percentage of total variation across studies. A random effects model was used because it is a more conservative method which considers heterogeneity among the included studies.[13](#dom13147-bib-0013){ref-type="ref"} Data from studies with more than one interventional arm with DPP‐4 inhibitors were considered as multiple comparisons and were included in the meta‐analysis after the sample sizes of the control groups had been equally split, as indicated by the Cochrane Handbook guideline.[13](#dom13147-bib-0013){ref-type="ref"} Publication bias was assessed by visual inspection of the asymmetry of the funnel plot and Egger\'s regression asymmetry test.[13](#dom13147-bib-0013){ref-type="ref"} *P* values were two‐tailed, and statistical significance was set at *P* \< .05.

3. RESULTS {#dom13147-sec-0007}
==========

3.1. Study selection {#dom13147-sec-0008}
--------------------

A flow chart outlining the study selection process is presented in Figure [S1](#dom13147-supitem-0001){ref-type="supplementary-material"}. A final total of eight RCTs were included in our study.[4](#dom13147-bib-0004){ref-type="ref"}, [5](#dom13147-bib-0005){ref-type="ref"}, [6](#dom13147-bib-0006){ref-type="ref"}, [7](#dom13147-bib-0007){ref-type="ref"}, [8](#dom13147-bib-0008){ref-type="ref"}, [9](#dom13147-bib-0009){ref-type="ref"}, [10](#dom13147-bib-0010){ref-type="ref"}, [11](#dom13147-bib-0011){ref-type="ref"}

3.2. Study characteristics and quality evaluation {#dom13147-sec-0009}
-------------------------------------------------

Of the eight included RCTs, one included two interventional arms with different doses of alogliptin (12.5 and 25 mg once daily), and these were included as two comparisons. The clinical and baseline patient characteristics for the included studies are presented in Table [1](#dom13147-tbl-0001){ref-type="table-wrap"}. All of the RCTs included patients already taking metformin, except for one study that included medication‐naïve patients,[4](#dom13147-bib-0004){ref-type="ref"} and there was considerable variation in HbA1c levels at baseline (7.5%‐11.0%). Different DPP‐4 inhibitors were used, including vildagliptin, sitagliptin, alogliptin, linagliptin and saxagliptin. The drop‐out rate was substantial for the included RCTs, and the strategies of considering observed cases and last observation carried forward were applied to handle this issue. The details of the quality evaluation are shown in Table [S1](#dom13147-supitem-0003){ref-type="supplementary-material"}. All of the included studies were double‐blind RCTs.

###### 

Baseline patient and clinical characteristics of the included studies

  Study               Design   N      Mean age, years   Sex, % men   BMI, kg/m^2^   Baseline HbA1c, %   T2DM duration, years   Add‐on therapy   Extension study   DPP‐4 inhibitor dose              SU dose                            Intermediate time point, weeks   Final time point, weeks   Drop out, %, and handling strategy
  ------------------- -------- ------ ----------------- ------------ -------------- ------------------- ---------------------- ---------------- ----------------- --------------------------------- ---------------------------------- -------------------------------- ------------------------- ------------------------------------
  Foley 2009          R, DB    811    54.8              55.8         30.7           8.7                 2.2                    N                N                 Vildagliptin, 50 mg twice daily   Gliclazide, 80‐320 mg once daily   24, 52                           104                       25.7%, LOCF
  Ahren 2010          R, DB    258    57.5              53.6         31.8           7.3                 5.7                    Y, Metformin     Y                 Vildagliptin, 50 mg twice daily   Glimepiride, 2‐6 mg once daily     24, 52                           104                       NR
  Matthews 2010       R, DB    1357   57.5              53.5         31.6           7.2                 5.7                    Y, Metformin     N                 Vildagliptin, 50 mg twice daily   Glimepiride, 2‐6 mg once daily     24, 53                           104                       37.6%, LOCF
  Seck 2010           R, DB    504    57.3              60.1         31.1           7.3                 5.8                    Y, Metformin     N                 Sitagliptin, 100 mg once daily    Glipizide, 5‐20 mg once daily      24, 54                           104                       56%, OC
  Gallwitz 2012       R, DB    504    59.8              60.5         30.3           7.7                 NR                     Y, Metformin     N                 Linagliptin, 5 mg once daily      Glimepiride, 1‐4 mg once daily     28, 52                           104                       23%, LOCF
  Goke 2013           R, DB    312    57.5              52.4         31.4           7.7                 5.5                    Y, Metformin     Y                 Saxagliptin, 5 mg once daily      Glipizide, 5‐20 mg once daily      24, 52                           104                       73%, LOCF
  Ahren 2014          R, DB    602    55.1              50.1         NR             8.2                 6.2                    Y, Metformin     N                 Sitagliptin, 100 mg once daily    Glimepiride, 2‐4 mg once daily     24, 52                           104                       33%, LOCF
  Del 2014, 12.5 mg   R, DB    1317   55.4              48.9         31.2           7.6                 5.6                    Y, Metformin     N                 Alogliptin, 12.5 mg once daily    Glipizide, 5‐20 mg once daily      26, 52                           104                       22%, LOCF
  Del 2014, 25 mg     R, DB    1322   55.4              50.8         31.2           7.6                 5.5                    Y, Metformin     N                 Alogliptin, 25 mg once daily      Glipizide, 5‐20 mg once daily      26, 52                           104                       22%, LOCF

Abbreviations: BMI, body mass index; DB, double‐blind; LOCF, last observation carried forward; N, no; NR, not reported; OC, observed cases; R, randomized; Y, yes.

3.3. Comparative glycaemic durability of DPP‐4 inhibitors and SUs {#dom13147-sec-0010}
-----------------------------------------------------------------

Treatment with DPP‐4 inhibitors was associated with significantly smaller changes in HbA1c levels from 24 to 28 weeks to 104 weeks (MD −0.16%, 95% CI −0.21 to −0.11; *P* \< .001; Figure [1](#dom13147-fig-0001){ref-type="fig"}A) and 52 weeks to 104 weeks (MD −0.06%, 95% CI −0.10 to −0.02; *P* = .001; Figure [1](#dom13147-fig-0001){ref-type="fig"}B) compared with SUs, with no considerable heterogeneity (I^2^ = 0%). A sensitivity analysis based on the omission of the study including medication‐naïve patients showed similar results (24‐28 weeks: MD −0.15%, 95% CI −0.20 to −0.10, *P* \< .001; 52 weeks: MD −0.06%, 95% CI −0.10 to −0. 02, *P* = .003).

![Forest plots for the comparative glycaemic durability of DPP‐4 inhibitors and SUs. A, Changes in HbA1c levels from 24 to 28 to 104 weeks of treatment; B, changes in HbA1c levels from 52 to 104 weeks of treatment. i.v., intravenous; s.d., standard deviation](DOM-20-1029-g001){#dom13147-fig-0001}

3.4. Publication bias {#dom13147-sec-0011}
---------------------

The funnel plots for the comparative effectiveness of DPP‐4 inhibitors and SUs for long‐term glycaemic control (Figure [S2](#dom13147-supitem-0002){ref-type="supplementary-material"}) were symmetrical on visual inspection, suggesting no significant publication bias. Egger\'s significance test also did not indicate the existence of publication bias (*P* = .542 and *P* = .388, respectively).

4. DISCUSSION {#dom13147-sec-0012}
=============

The present meta‐analysis showed that treatment of patients with T2DM with DPP‐4 inhibitors was associated with a significantly smaller change in the HbA1c level from an intermediate time point to the end of 104 weeks of follow‐up as compared with treatment with SUs, suggesting that DPP‐4 inhibitors offer better glycaemic durability than SUs. Considering the other advantages of DPP‐4 inhibitors over SUs, such as the lower incidence of adverse events, including hypoglycaemia, and the lesser impact on body weight, the results of the present study indicate that DPP‐4 inhibitors might be a preferable treatment choice for patients with T2DM as an add‐on medication with metformin.

Diminished β‐cell function has been recognized as an important step in the pathogenesis of T2DM.[14](#dom13147-bib-0014){ref-type="ref"} Insulin resistance, as an initial event during the pathogenesis of T2DM, leads to accelerated insulin secretion by islet β cells, which eventually results in the overwork of the β cells and subsequent deterioration of β‐cell function.[15](#dom13147-bib-0015){ref-type="ref"} Because the primary pharmacological effects of SUs are the stimulation of insulin secretion by β cells, the significant glucose‐lowering effect that can be observed during the early phase of the treatment eventually fades or even disappears with long‐term treatment. This so‐called monotherapy failure with SUs has been linked to continuous loss of functional islet β cells and impaired β‐cell function during the progression of T2DM.[16](#dom13147-bib-0016){ref-type="ref"} Our finding that DPP‐4 inhibitors have better glycaemic durability than SUs is consistent with the results of previous studies demonstrating that DPP‐4 inhibitors may have beneficial effects on the preservation of β‐cell numbers and β‐cell functions. An early study in rats with streptozotocin‐induced diabetes found that the DPP‐4 inhibitor P32/98 had a dose‐dependent preventive effect on streptozotocin‐induced β‐cell apoptosis, suggesting that the therapeutic effects of DPP‐4 inhibitors may involve the prevention of functional β‐cell loss.[17](#dom13147-bib-0017){ref-type="ref"} By contrast, treatment with glipizide, was not associated with restoration of β‐cell mass.[18](#dom13147-bib-0018){ref-type="ref"} Subsequent experimental studies also indicated that some DPP‐4 inhibitors had protective effects on β‐cell mass and function.[19](#dom13147-bib-0019){ref-type="ref"} These results suggest that the preservation of β‐cell mass and function is a common effect of DPP‐4 inhibitors. Further studies are needed to confirm our hypothesis that DPP‐4 inhibitors confer better protective effects on β‐cell mass and function in humans, particularly as compared with SUs.

Our results have limitations that should be considered when interpreting the results. First, we tested our hypothesis that DPP‐4 inhibitors offer better glycaemic durability than SUs using the change in the HbA1c level from an intermediate time point to the final time point as the outcome. To minimize the influence of the choice of the intermediate time point on the meta‐analysis results, we chose two intermediate time points (26 and 52 weeks) for evaluation. Since a generalized index for glycaemic durability is lacking for current medical research, our approach may be a practical method for evaluating glycaemic durability of OADs in diabetes research. As mentioned in a previous meta‐analysis with the outcome of glycaemic durability[3](#dom13147-bib-0003){ref-type="ref"} and the curves of treatment effects of our included RCTs,[4](#dom13147-bib-0004){ref-type="ref"}, [5](#dom13147-bib-0005){ref-type="ref"}, [6](#dom13147-bib-0006){ref-type="ref"}, [7](#dom13147-bib-0007){ref-type="ref"}, [8](#dom13147-bib-0008){ref-type="ref"}, [9](#dom13147-bib-0009){ref-type="ref"}, [10](#dom13147-bib-0010){ref-type="ref"}, [11](#dom13147-bib-0011){ref-type="ref"} the maximum reduction in HbA1c by DPP‐4 inhibitors appeared at \~24 to 28 weeks after the initiation of the treatment; therefore, it is logical to evaluate the glycaemic durability after the stabilization of the DPP‐4 inhibitors\' therapeutic effects. In addition, our conclusions were confirmed by the consistent results obtained for changes in HbA1c levels from two intermediate time points to the final visit. Secondly, the difference in treatment effect size was not particularly large, and the clinical relevance of the results deserves further confirmation; however, because HbA1c is a relatively stable variable that is considered a reflection of glucose levels within 3 months and has been linked to the risk of diabetes complications, the results of our study may indicate the benefits of long‐term administration of DPP‐4 inhibitors over SUs on clinical outcome. Thirdly, the total follow‐up duration was limited to 104 weeks. Obviously, changes in glycaemic control after treatment with DPP‐4 inhibitors vs SUs beyond the 2‐year duration deserve further investigation. Fourthly, our study included two extension studies based on original studies with a 52‐week follow‐up, which may introduce selection bias because patients with unsatisfactory glucose control during follow‐up for the original studies may not have participated in the extension studies; however, a meta‐analysis limited to studies originally designed with a 104‐week follow‐up produced similar results. Fifthly, the participant drop‐out rates varied among the RCTs, which may have influenced the quality of the study. Finally, although no significant statistical heterogeneities were observed among the included RCTs, these studies varied with regard to the study and patient characteristics.

In conclusion, long‐term treatment with DPP‐4 inhibitors conferred better glycaemic control compared with SUs in patients with T2DM, which may reflect that DPP‐4 inhibitors better preserve islet β‐cell function than do SUs.
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**Figure S1.** Flow chart of study selection.
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**Figure S2.** Funnel plot for the glycemic durability of DPP4 inhibitors and SUs. A, Changes in HbA1c levels from 24 to 28 to 104 weeks of treatment; B, changes in HbA1c levels from 52 to 104 weeks of treatment.
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**Table S1.** Details of study quality as evaluated by Cochrane\'s risk of bias tool.
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